1.29
Virax Biolabs Group Ltd stock is traded at $1.29, with a volume of 326.82K.
It is down -12.35% in the last 24 hours and down -31.38% over the past month.
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
See More
Previous Close:
$1.4717
Open:
$1.4665
24h Volume:
326.82K
Relative Volume:
0.93
Market Cap:
$5.60M
Revenue:
$79,300
Net Income/Loss:
$-6.92M
P/E Ratio:
-0.068
EPS:
-18.9818
Net Cash Flow:
$-5.34M
1W Performance:
-5.15%
1M Performance:
-31.38%
6M Performance:
-50.19%
1Y Performance:
+51.76%
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
Name
Virax Biolabs Group Ltd
Sector
Industry
Phone
-
Address
-
Compare VRAX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VRAX
Virax Biolabs Group Ltd
|
1.29 | 5.60M | 79,300 | -6.92M | -5.34M | -18.98 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Virax Biolabs Group Ltd Stock (VRAX) Latest News
Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes - TipRanks
Virax Biolabs shares T-Cell dysfunction findings - Investing.com India
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting - Yahoo Finance
Virax Biolabs to Present at World Immune Regulation Meeting - TipRanks
Can Virax's T-Cell Research at WIRM 2025 Advance Post-Infection Syndrome Treatment? - StockTitan
Cosmos Health expands distribution of Avian Influenza kits - MSN
Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8% - Defense World
Virax Biolabs aligns with US vaccine transparency efforts By Investing.com - Investing.com South Africa
Virax Biolabs Aligns with US Health Department on Vaccine Transparency - TipRanks
How Virax's Vaccine Testing Tech Could Capitalize on New Government Transparency Push - StockTitan
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency - Benzinga
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Market Watch: Virax Biolabs Group Ltd (VRAX)’s Noteworthy Drop, Closing at 1.71 - The Dwinnex
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January - Armenian Reporter
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait - Yahoo Finance
Cosmos Health secures exclusive distribution agreement with Virax Biolabs - Yahoo Finance
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries - Lelezard
Virax Biolabs Group Ltd (VRAX) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know - MSN
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 38.5% in December - Defense World
Virax Biolabs Achieves Shareholder Approvals at Adjourned Annual Meeting - TipRanks
Stock Region Signal Report - substack.com
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Virax Biolabs Announces Strategic Goals and Developments for 2025 - TipRanks
Virax Biolabs Advances T-Cell Platform with $7.3M War Chest, Expands European Distribution Network - StockTitan
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect across the European Union, Norway, and Switzerland - Marketscreener.com
Virax Biolabs Expands ImmuneSelect Reach in Europe - TipRanks
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland - Yahoo Finance
Virax Biolabs Group First Half 2025 Earnings: US$0.89 loss per share (vs US$1.64 loss in 1H 2024) - Simply Wall St
Virax Biolabs Sees Asset Growth Amid Financial Loss - TipRanks
ARMISTICE CAPITAL, LLC Acquires New Stake in Virax Biolabs Group Ltd - GuruFocus.com
Virax Biolabs announces 2024 annual meeting - Investing.com India
Virax Biolabs announces 2024 annual meeting By Investing.com - Investing.com UK
Virax Biolabs Sets Date for 2024 AGM - TipRanks
Virax Biolabs announces distribution agreement with Europa Biosite - TipRanks
Virax Biolabs Expands Reach with Europa Biosite Deal - TipRanks
EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland - Yahoo Finance
Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland - StockTitan
Pre-market Movers: ALZN, VRAX, APDN, LQDA... - RTTNews
Analyzing the Impact of Earnings Reports on Virax Biolabs Group Ltd Inc. (VRAX) Price Performance - The InvestChronicle
Daily Progress: Virax Biolabs Group Ltd (VRAX) Gain 14.20, Closing at 1.85 - The Dwinnex
Virax Biolabs Plans New Share Offering - TipRanks
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 72.2% in September - Defense World
Charting the Course: Virax Biolabs Group Ltd’s VRAX Stock Prospects - The InvestChronicle
How did Virax Biolabs Group Ltd (VRAX) fare last session? - US Post News
Daily Market Movement: Virax Biolabs Group Ltd (VRAX) Sees a -3.56 Decrease, Closing at 2.44 - The Dwinnex
Virax Biolabs Group Ltd (VRAX)’s Day in Review: Closing at 2.84, Up by 9.65 - The Dwinnex
Virax Biolabs Group Ltd Stock (VRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):